Thus, targeting OxPhos (whether with IACS‐010759, tigecycline, etc.)along with select BCL2‐family members [21] may be an effective means to achieve synergy against high‐grade B‐cell lymphomas (Fig. 7). Here, BCL2 is linked to B-cell non-Hodgkin lymphoma.